Asterias Biotherapeutics Announces Notice Of Grant Award With CIRM For Phase 1/2a Clinical Trial Of AST-OPC1 In Complete Cervical Spinal Cord Injury /PRNewswire/ -- Asterias Biotherapeutics, Inc. announced today that the Company has signed a Notice of Grant Award with the California Institute of Regenerative Medicine , effective , 2014. The NGA provides for the immediate release of Clinical Development payments and the release of additional grant funds pursuant to the previously announced CIRM grant award for clinical development of Asterias' product, AST-OPC1.
http://ift.tt/1sHraK6
http://ift.tt/1sHraK6
No comments:
Post a Comment